|Mr. Glenn Mario Saldanha||Chairman, MD & CEO||141M||N/A||47|
|Mr. Harish Kuber||Company Sec. & Compliance Officer||390k||N/A||N/A|
|Mrs. Cherylann Maria Pinto B.Pharm||Director of Corp. Affairs & Exec. Director||38.76M||N/A||50|
|Mr. V. S. Mani||Pres & Global CFO||N/A||N/A||52|
|Dr. Fred Grossman D.O., FAPA||Pres & Chief Medical Officer||N/A||N/A||N/A|
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, the United States, Latin America, Europe, and internationally. The company provides branded and generic formulations in therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its products under development comprise GBR 1302 for breast and gastric cancer; GBR 1342 for multiple myeloma; GBR 1372 for colorectal cancer; GBR 8383 for multiple cancers; GBR 830 for atopic dermatitis; GRC 39815 for COPD and IPF; GSP 301 for allergic rhinitis; GSP 304 for COPD; GBR 310 for Asthma and CIU; and GRC 27864 for chronic pain indications. The company was founded in 1977 and is based in Mumbai, India.
Glenmark Pharmaceuticals Limited’s ISS Governance QualityScore as of February 1, 2018 is 5. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 1; Compensation: 7.